Mannkind reported $-29023000 in Pre-Tax Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Adma Biologics ADMA:US $ -13.76M 4.57M
Chemocentryx CCXI:US $ -31.65M 6.96M
Dynavax Technologies DVAX:US $ 129.37M 96.52M
Halozyme Therapeutics HALO:US $ 30.01M 51.62M
Immunogen IMGN:US $ -62.02M 37.88M
Insmed INSM:US $ -95144000 908K
Karyopharm Therapeutics KPTI:US $ -48941000 7.67M
Macrogenics MGNX:US $ -41.3M 25.14M
Mannkind MNKD:US $ -29.02M 3.02M
Minerva Neurosciences NERV:US $ -8.72M 1.05M
Novavax NVAX:US $ -509.07M 715.14M
Peregrine Pharmaceuticals PPHM:US $ 0.59M 1.66M
Sanofi SAN:FP € 2660M 305M
Xencor XNCR:US $ -33.98M 57.57M